Actuate Therapeutics Receives FDA IND Clearance for Oral Elraglusib
Actuate Therapeutics announced FDA clearance of an Investigational New Drug (IND) application for its oral elraglusib formulation, enabling a Phase 1/2 study in advanced cancer patients, including those with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers. The company plans to initiate the study in the second half of 2026, aiming to optimize drug exposure and response with the oral tablet. Additionally, Actuate expects preclinical results for elraglusib combined with RAS inhibitors in mid-2026 and appointed Dr. Martin Huber to its Board of Directors. However, the company also noted its financial condition raises substantial doubt about its ability to continue as a going concern beyond July 2026 without additional capital.
Key Highlights
- FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients.
- Phase 1/2 study initiation planned for 2H 2026, focusing on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers.
- Oral formulation aims to enhance patient convenience, broaden clinical utility, and improve pharmacokinetic exposure.
- Preclinical results for elraglusib plus RAS inhibitor combination expected in mid-2026.
- Dr. Martin Huber, an industry veteran, joined Actuate's Board of Directors.
- Elraglusib IV formulation previously showed statistically significant improvement in overall survival in mPDAC Phase 2.
- Company requires additional capital to finance operations beyond July 2026.